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Abstract
Calpain 3 (CAPN3) is a cysteine protease that when mutated causes Limb Girdle Muscular Dystrophy 2A. It is thereby the
only described Calpain family member that genetically causes a disease. Due to its inherent instability little is known of its
substrates or its mechanism of activity and pathogenicity. In this investigation we define a primary sequence motif
underlying CAPN3 substrate cleavage. This motif can transform non-related proteins into substrates, and identifies .300
new putative CAPN3 targets. Bioinformatic analyses of these targets demonstrate a critical role in muscle cytoskeletal
remodeling and identify novel CAPN3 functions. Among the new CAPN3 substrates are three E3 SUMO ligases of the Protein
Inhibitor of Activated Stats (PIAS) family. CAPN3 can cleave PIAS proteins and negatively regulates PIAS3 sumoylase activity.
Consequently, SUMO2 is deregulated in patient muscle tissue. Our study thus uncovers unexpected crosstalk between
CAPN3 proteolysis and protein sumoylation, with strong implications for muscle remodeling.
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Introduction
Regulated proteolysis is an indispensible mechanism for cell
physiology. By controlling protein degradation, protein levels can
be modulated without generating toxic waste products. Proteases
are classified according to their reactive site residues into clans and
families. The clan of cysteine proteases includes the Calpain
family. Calpains are non-denaturing proteases that respond to
local changes in calcium. Amongst their many functions, Calpains
are involved cytoskeleton remodeling [1].
Calpain 3 (CAPN3) is a muscle specific Calpain family member.
When mutated it causes Limb-Girdle Muscular Dystrophy
(LGMD) 2A (OMIM#253600, the most common form of LGMD
in many populations). [2] It is currently not known how CAPN3
functions and how its dysfunction causes disease. CAPN3 shares
,50% identity with Calpain 1 and 2 (MIM*114220 and *114230,
respectively)[3] on amino acid level, but is unique in that it
contains three specific insertion sequences (NS, IS1 and IS2) which
have to be autolytically removed for CAPN3 to become
proteolitically active. Like Calpains 1 and 2 CAPN3 has a
calcium-sensing domain, which operates with nanomolar sensitiv-
ity and influences protease activation and activity [4]. In muscle
tissue most, but not all, of the CAPN3 protein can be found in an
inactive form bound to the sarcomere. Upon stimulation, CAPN3
both activates and deactivates itself rapidly through autolysis of the
insertion sequences. After removal of the IS1 sequence the protein
continues as a proteolytically active intramolecular heterodimer.
Subsequent continued autolysis results in protease deactivation.
In vitro studies have shown that within 10 minutes autolysis can
result in its total destruction [3], but this depends on free [Ca2+]
[4]. Due to this instability little is known of its substrates and its
mechanism of action, but it has been hypothesized that CAPN3
must have a very short range activity. [5] Intriguingly, CAPN3
cleavage has been suggested to be both very specific[4] and very
general[5] in nature. Defining the motif for CAPN3 mediated
cleavage would therefore provide important insight in the role of
this enigmatic protein in local tissue remodeling.
Previous proteomic[6] and yeast-two-hybrid studies have
identified several substrates that collectively hint at a role for
CAPN3 in cytoskeleton remodeling[7,8], just like its family
members. However, the number of characterized substrates is
small, and does not allow for a comprehensive investigation into
CAPN3 cleavage and function. Large peptide-based libraries have
been used to determine protease cleavage motifs of Calpain 1 and
2. [9] However, it has been postulated that Calpain proteases not
only recognize a primary sequence motif, but also a three-
dimensional fold[10], obstructing cleavage motif identification by
this strategy as peptide libraries likely lack essential folding
properties. Multiple Calpain 1 and 2 substrates have been shown
to contain a PEST domain. Deletion of this domain renders
certain substrates insensitive to proteolytic cleavage. [11] Howev-
er, in many other cases the PEST site has no influence on Caplain-
mediated proteolysis[12], leaving the role of these sequences
uncertain. Comparison of experimentally determined cleavage
sites of Calpains 1 and 2 showed several amino acids to be
overrepresented, but this proved inconclusive[13] and does not
PLoS ONE | www.plosone.org 1 August 2010 | Volume 5 | Issue 8 | e11940compare well with peptide-based results. [9] In fact, some
proteases are able to cleave after every possible amino acid, [14]
indicating that in addition to the primary sequence, surface
exposure and peptide flexibility are important determinants of
Calpain substrate recognition and cleavage [14].
From this we hypothesized that a cleavage motif might only be
identified from peptide analysis, when the determinants of
presentation and flexibility are taken into account.
There are many methods in literature for predicting substrates
and cleavage sites by proteases. [15] In this investigation we used a
bio-informatics approach to derive a CAPN3 substrate target
sequence. We show that the CAPN3 consensus cleavage motif that
we have identified can transform non-substrate proteins into
substrates and can be used to predict and identify new substrates.
Our data supports CAPN3 to be a regulator of rapid local changes
in cytoskeletal protein content, identifies novel roles for CAPN3,
and highlights CAPN39s role as a molecular switch in muscle
remodeling.
Results
Identification of a functional CAPN3 cleavage motif
We hypothesized that CAPN3 substrates harbor a uniform
cleavage motif. From literature we identified several substrates
(Table 1). [8,16,17] As substrate criterion we only considered
proteins for which the actual cleavage fragments had been
experimentally tested. We screened these proteins for the presence
of similar sequences based on amino acid structure using the
computer algorithm TEIRESIAS. [18] This yielded a motif of 10
amino acids with 4 key residues: [LIMV]1-X2-X3-X4-X5-[LIMV]6-
X7-X8-[LIMV]9-[DE]10 in which X represents any amino acid
(Table 1).
The position of this motif is in good agreement with estimated
fragment sizes from published western blots. We used the first
substrate in our motif screen, AHNAK, to experimentally confirm
that cleavage occurs within close vicinity of the motif. The HIS-
tagged N-terminal domain of AHNAK was co-expressed with
CAPN3 as described previously [17] and the AHNAK protein
fragments were purified by means of their HIS6-tag, resolved on
SDS-PAGE gels, and subjected to mass spectrometry analysis. The
peptide nearest to the HIS6-tag that was solely indentified in the
full-length protein (Figure 1A) contained the predicted cleavage
sequence, showing that the motif is at the site of cleavage.
We next asked whether this motif contains all of the essential
information for CAPN3 mediated cleavage. To investigate this we
used a fusion protein (BG) consisting of an N-terminal b-
Galactosidase and a C-terminal GFP connected by a flexible linker
(Figure 1B). The 10 amino acid sequence identified in AHNAK-N
was inserted into the linker (Figure 1B), and fusion constructs with
and without the AHNAK motif were co-expressed with CAPN3 or
its proteolytically inactive mutant CAPN3
C129S. [3] Figure 1C
shows that CAPN3 is able to cleave the fusion protein only when it
contains the AHNAK peptide, while CAPN3
C129S is unable to do
so. This indicates that the AHNAK-N peptide contains all of the
essential information for CAPN3 mediated cleavage. Correct
CAPN3 expression was confirmed by western blot analysis using
a CAPN3-specific antibody (Figure 1D).
We further verified that CAPN3 recognizes the motif. We
proceeded by introducing the two additional predicted AHNAK
peptides into our fusion protein and found that they were also
cleaved upon co-expression with CAPN3 (Figure 1E), consistent
with previous data that CAPN3 cleaves AHNAK at multiple sites.
[17] One AHNAK peptide sequence identified by Blast similarity
to the confirmed AHNAK-N peptide however was not cleaved
(Figure 1E). Interestingly, this peptide maps to an AHNAK
domain that was previously excluded to serve as a substrate for
CAPN3 [17] and deviates from the motif only at position 9 where
it contains a proline instead of [LIMV]. From this we conclude
that CAPN3 indeed recognizes a primary sequence motif.
Assignment of four key residues
The remaining peptides from the described substrates were all
cleaved by CAPN3 in our assay (Table 1, Figure S1). As
mentioned before the motif consists of a backbone and 4 key
residues. We selected two peptides (the AHNAK peptide and the
predicted Filamin C (FLNC, MIM*102565) peptide) based on
their most dissimilar backbone residues and subjected them to
extensive mutational analysis (Table 1). Mutation of positions 1
and 10 (key residues 1 and 4) to alanine abolishes cleavage.
Alanine mutation of position 9 (key residue 3) has no strong effect.
However, introducing a proline at this position (a mutation that
mimics the Blast similarity result of Figure 1E) prevents cleavage,
whereas a proline insertion at non-key residue position 2 does not
affect cleavage. From the naturally occurring peptides in Table 1 it
can be inferred that in the backbone of the motif almost every
combination of amino acids is allowed. From this analysis we
conclude that the 10 amino acids spanning CAPN3 cleavage motif
consist of 4 key residues: amino acids 1 and 10 are essential, where
5 and 9 are of only moderate importance. It appears that the span
width of the motif (10 aa) can be relatively variable, as backbone
deletions do not always impair cleavage efficiency (Table 1). This
information led to the identification of a putative cleavage site in
AHNAK (AHNAK-C2.2), which had been described[17] and
indeed was cleaved in our assay (Table 1).
Predicting new CAPN3 substrates
All previous studies focused on known substrates, whereas our
ultimate goal was to capture the general identifier of CAPN3
substrates and so to predict and verify the Calpainome of CAPN3.
We therefore screened the motif against the UniProt database and
retrieved 8,181 protein hits in human alone. While not entirely
impossible (CAPN3 is hypothesized to cleave virtually everything
within its vicinity due to its short half-life)[5] this seems unlikely
and probably other constraints apply; an obvious one being that
CAPN3 is muscle specific. We tested several candidate peptides
based on their co-occurence with CAPN3 or myopathy in
PubMed abstracts, and found some of them to be cleaved by
CAPN3 (Table 1) confirming the predictive potential of the motif.
Some peptides however did not show cleavage (see Discussion).
To generate a more specific list of putative substrates we created a
more stringent motif by including information about the backbone
residues. We added the amino acid identities for each of the 10
positions for the best performing peptides in our cleavage assay (see
Methods section). This motif will therefore not represent all CAPN3
substrates, but does leave us with a more workable subset of potential
substrates. The stringent motif ([VLM][PGED][SAGEKL] putX(0,1)
[VAIML][ESPQLK][GKEY][VLA][ED]) predicts 325 substrates in
human (Table S1). We selected a subset of substrate peptides
representative for the functional diversity of the 325 proteins and
which share less then 50% sequence identity to the peptides used to
construct the motif. These peptides were tested positive in the BG
fusion protein assay with a success rate of 88% (14/16 peptides:
Table 1).
We next investigated if the presentation of the motif in the
native proteins might allow for recognition by CAPN3. For 18
predicted substrates the crystal structure had been resolved,
showing clear surface presentation of the motif in all cases (Table
S1). Moreover, secondary structure predictions suggest that 67%
A Calpain 3 Cleavage Motif
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Described substrates
[LIMV]X(4)[LIMV]X(2)[LIMV][DE]
Motif Cleaved Prot ID Gene ID Location Protein
V PSAN IE GL E + Q09666 AHNAK 356–381 AHNAK-N (16)
L PAIH VE GL D +/2 Q09666 AHNAK 5124–5159 AHNAK-C1 (16)
L PGIG VQ GL E +/2 Q09666 AHNAK 5468–5503 AHNAK-C2 (16)
V EECY VS EL D + Q14315 FLNC 2451–2486 Filamin C (15)
I TKEC VM RV D + Q9Y490 TLN1 330–365 Talin (8)
I KKKL VQ RL E + Q9Y490 TLN1 907–942 Talin (8)
L YPEP VR VL E + Q8WZ42 TTN 1843–1878 Titin1607–2167 (8)
V RYDG IH YL D + Q8WZ42 TTN 1887–1922 Titin1607–2167 (8)
L TTER LV HV D + Q8WZ42 TTN 795–830 Titin741–948 (8)
No motif Q8WZ42 TTN No hit Titin952–1540 (8)
V KYEG IG PV D +/2 O60504 SORBS3 117–152 Vinexin (8)
V WYFG LH YV D +/2 P15311 EZR 30–65 Ezrin (8)
I GEET VI TV D ND P21333 FLNA 1664–1699 Filamin A (8)
L EECY VT EI D ND P21334 FLNA 2373–2408 Filamin A (8)
V PDVS LE GP E 2 Q09666 AHNAK 1293–1302 AHNAK-R (16)
Mutations in motif sequence
AHNAK-N peptide FLNC peptide
Motif Cleaved Motif Cleaved
V PSAN IE GL E + V EECY VS EL D +
V PSAN IE GP E 2 V EECY VS EP D 2
V PSAN IE GL A 2 V EECY VS EL A +/2
V PSAN IE GL K +/2 V EECY VS EL K ND
A PSAN IE GL E 2 A EECY VS EL D 2
V PSAN IE GA E + V EECY VS EA DN D
V PSAN IE GM E + V EECY VS EM DN D
V PSAN IE GI E + V EECY VS EI DN D
V PSAN A EG L E + V EECY A SE L DN D
V PSAN A EG A E + V EECY A SE A D +/2
V PSAN K EG L E 2 V EECY K SE L D 2
V PSAN E EG L E +/2 V EECY E SE L D 2
V ESAN IE GE E ND V EECY VS EE D 2
VP .AN IE GL E +/2 VE .CY VS EL D 2
D PSAN D EG D D 2 V PECY VS EL D +
Predicted substrates
[LIMV]X(3,4)[LIMV]X(2)[LIMV][DE]
Motif Cleaved Protein ID Gene ID
V GIQ. LP EV E + Q09666 AHNAK
L DLRS IK EV D + P20810 CAST
M PSFK MP KV D + Q8IVF2 AHNAK2
L IARM VR NM D 2 P20807 CAPN3
L IARM VR G M D +/2 P20807 CAPN3 mutation
L EKK. VL YV D + P20807 CAPN3
I YPAT IA SI D +/2 Q16637 SMN1
A Calpain 3 Cleavage Motif
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segments, which is consistent with predictions for Calpain 1 and 2.
[13] (data not shown) This indicates that the motif adopts a
tertiary conformation and is presented in a flexible loop, consistent
with the large backbone of the motif. [9] Finally, the structure of
the described substrate FLNC is predicted to fit into the active site
of CAPN3 in a docking experiment (Figure S2). Though not a
formal proof, these results support our biochemical experiments
and predict that the peptide motif can be recognized by CAPN3 in
its natural context.
To confirm that the restricted motif yields biologically relevant
candidate substrates we performed multiple biosemantic analyses.
As CAPN3 is muscle-specific we can only analyze co-expression in
muscle, which is less informative than when comparing expression
in multiple tissues. To overcome this limitation, we did a concept
analysis based on MedLine abstracts [19] to confirm that the
restricted motif yields relevant predictions based on co-occurrence
in the biomedical literature. [19] Figure S3A shows the concepts
that are most frequently found to be associated with our putative
325 substrates. The top ranked concept is Cytoskeletal Proteins,
consistent with the hypothesis that CAPN3 is a cytoskeleton
remodeler. In the right panel of Figure S3A we listed those
proteins that associate most strongly with the concept cytoskeleton.
Only 2 of the 29 associated putative substrates were used in the
definition of the cleavage motif, the others are new cytoskeletal
CAPN3 substrate candidates. Other concepts associated with the
325 putative substrates relate to cell architecture and open the
possibility for a role of CAPN3 in mitosis. The latter is interesting
as a recent study reported on a population of CAPN3 expressing
myogenic reserve cells in which CAPN3 indirectly regulated
MyoD. [20] We next grouped all 325 proteins based on
conceptual overlap before annotating with concepts, and plotted
the results in a heat map (Figure S3B, Table S2). This gives a
better view of which type of proteins can be found in the list.
Again, we find several clusters of structural proteins. Other
proteins in the list appear to participate in different biological
processes such as mitosis, vesicle trafficking, apoptosis, transcrip-
tion, calcium transport. For several of these processes some
indication of CAPN3 involvement can be found in literature.
[21–24] In conclusion, based on MedLine abstracts the putative
substrates are strongly associated with the cytoskeleton. Additional
GO term pathway annotation analysis (Figure S3C, Table S3)
shows the strongest overrepresentation with GO terms that relate
to cell structure and cyto-architecture. This corroborates on the
hypothesis of CAPN3 being a cytoskeleton remodeler and
strengthens our belief that we have identified a genuine CAPN3
cleavage motif.
However, this does not prove that all 325 proteins are in vivo
substrates. We therefore proceeded with studying muscle protein
homogenates from Calpainopathy patients for their levels of two
predicted substrates that represent some of the functional diversity
of the predicted substrates: the cytoskeletal protein Tropomyosin
(TPM2, MIM*190990), and the myogenic differentiation protein
Brother of CDO precursor (BOC, MIM*608708). Figure 2 shows
an accumulation of Tropomyosin (Figure 2A) and BOC (Figure 2B)
in skeletal muscle of Calpainopathy patients compared to healthy
[VLM][PGED][SAGEKL]{G}X(0,1)[VAIML][ESPQLK][GKEY][VLA][ED]
Motif Cleaved Protein ID Gene ID
LPAmkAKGLE + Q10567 AP1B1
LPAvkAKGLE + P63010 AP2B2
LGLvpVEEVD + Q9BWV1 BOC
MEGtvAPEAE 2 P49711 CTCF
LGSfnLEKVE + Q13426 XRCC4
VPLssAEEAE + Q8WZA1 POMGNT1
VPAayVKKLD + Q13813 SPTAN1
LGAlfLEYVD + Q5TBA9 FRY
LPApcASKVE + Q9UBL6 CPNE7
VDEeaMEKAE + Random Random
VDLv.MQKVE + Q5VT25 CDC42BPA
LGEepLLEVE + Q9UNK9 ANGEL1
LPStcLQKVE + Q00975 CACNA1B
LGEvqAEKAD 2 O94911 ABCA8
LGGldVLEAE + Q5SGD2 PPM1L
LEEk.LKEAE +/2 P07951 TPM2
Upper part: List of described CAPN3 substrates in which the putative CAPN3 cleavage motif was identified. For each substrate the peptide motif is shown, with key
residues spaced and underlined. The peptides were tested for cleavage potential in a BG fusion protein and judged as cleaved (+), partially cleaved (+/2), or not cleaved
(2). In Figure 1F BGn (with peptide from AHNAK-N) is a good (+) substrate, BGc1 and -c2 are moderate (+/2), and BGr is bad (2). In addition, the protein and gene ID
are given, the location of the motif, and the literature reference. Titin952–1540 and AHNAK-R were described as non-substrates and contain no motif sequence. For
AHNAK-R a peptide with Blast homology to the peptide from AHNAK-N is shown, with in bold the residue that is not conform the cleavage motif. Middle part: Single
mutants of the AHNAK-N and FLNC peptides were analyzed for cleavage potential. Mutated residues are shown in bold. Lower part: Several candidate peptides
conforming to the general motif or the specific motif were analyzed for cleavage potential. Most peptides were also tested in a reverse orientation of the fusion proteins
(GB, N-terminal GFP and C-terminal b-Galactosidase), never to give a discrepant result. Representative western blots for table 1 are included in Figure S1.
doi:10.1371/journal.pone.0011940.t001
Table 1. Cont.
A Calpain 3 Cleavage Motif
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CAPN3 cleavage motif we find explainable disturbances in the
levels of two predicted substrates in patients.
We selected one predicted substrate, PIAS3 (MIM*605987), for
furtherinquiry,because ithas twohomologous familymembers that
contain the general motif (PIAS1 and PIAS2) and a third family
member without motif (PIAS4). PIAS3 is an ubiquitously expressed
E3 SUMO ligase (Figure 2C) implicated in many signaling
pathways including NFkB[25], which is perturbed in LGMD2A.
[22] We first verified the levels of PIAS3 in CAPN3 deficient muscle
sections (Figure 2D). This provided evidence for a slight increase in
Calpainopathy tissue, compared to disease controls. To confirm
that PIAS3 can be cleaved by CAPN3 we co-expressed FLAG-
taggedPIAS3with CAPN3and observeda cleavagefragmentofthe
predicted size (Figure 2E). PIAS1 and PIAS2, which contain the
general CAPN3 cleavage motif, are similarly cleaved (Figure 2E).
However,PIAS4,whichhasneithermotif,isnotcleaved(Figure2E),
showing that our motif can not only predict new targets but can also
differentiate between homologous family-members based on
potential substrate properties.
As mentioned above PIAS3 has E3 SUMO ligase activity
(Figure 2C), which we expected to be regulated by CAPN3
proteolysis. When we co-expressed HIS6-tagged SUMO2 with
PIAS3 and CAPN3 in an in vivo sumoylation assay, cleavage of
PIAS3 impaired its sumoylation activity (Figure 2F). We confirmed
our observation with a HIS6 pull-down (Figure S4), proving that
this loss of signal involves covalently conjugated SUMO2 moieties.
Furthermore, PIAS3 has the capacity to autosumoylate and
CAPN3 cleavage completely abolishes this auto-sumoylation
(Figure S4), thus negatively regulating PIAS3 activity.
Based on these results we were interested to see whether PIAS
activity can be detected in skeletal muscle sections. We performed
an immunofluorescent staining for SUMO2 in muscle cryosections
of two patients with highest PIAS3 levels (P2 and P7 in Figure 2D)
(Figure S5), hypothesizing that in absence of CAPN3 the PIAS
proteins are not cleaved and therefore more active, resulting in
higher sumoylation. In healthy control tissue distinct nuclear
speckles (possibly PML bodies[26]) are visible in non-muscle cells.
In muscle nuclei these speckles cannot be detected. In the CAPN3
deficient muscle sections however, nuclear speckle staining can
also be observed in myonuclei, indicating increased sumoylation in
Figure 1. A peptide cleavage motif identifed in CAPN3. A) Cells
were transiently co-transfected with a HIS-VSV tagged AHNAK-N
domain and CAPN3 (active) or CAPN3
C129S (inactive). Cells were lysed
and analyzed on western blot for cleavage with a VSV antibody.
Lane1=AHNAK-N+CAPN3
C129S, Lane2=AHNAK-N, Lane3=AHNAK-
N+CAPN3. Separately, HIS-tagged AHNAK proteins were purified and
isolated from Coomassie Blue stained gels as indicated with the boxed
bands, and analyzed with LC-MS. The spectrum depicts the most N-
terminal peptide that was only identified in full-length AHNAK-N, and is
therefore likely at the site of cleavage. B) Schematic representation of
the b-Galactosidase-GFP (BG) fusion protein with the AHNAK-N peptide
motif introduced into the linker region. C+D) BG fusion constructs with
or without AHNAK-N peptide were co-expressed with active or inactive
CAPN3, and cells were analyzed on western blot for cleavage with
specific antibodies for GFP (C) or CAPN3 (D). 1=non-transfected,
2=BG+CAPN3, 3=BGpeptide+CAPN3, 4=BGpeptide+C129S,
5=CAPN3, 6=C129S. Arrows denote uncleaved (120 kDa) and cleaved
(25 kDa) BG fusion protein (C) or inactive (94 kDa) and active (55 kDa)
CAPN3 (D). E) as in C), but now the cleavage motifs identified in AHNAK-
N domain, AHNAK-C1 and AHNAK-C2 domains are analyzed in the BG
fusion protein, as is a homologous peptides found in the AHNAK-
Repeat domain, which does not conform to the motif. + and – refer to
active and inactive CAPN3 respectively. All cleavage experiments were
performed in HEK-293T and MCF7 cells, with comparable results.
doi:10.1371/journal.pone.0011940.g001
A Calpain 3 Cleavage Motif
PLoS ONE | www.plosone.org 5 August 2010 | Volume 5 | Issue 8 | e11940Figure 2. Verification of putative CAPN3 targets. A,B,D) Skeletal muscle homogenates of 5–7 Calpainopathy patients (P1-7), 1–2 healthy
controls (H1-2) and 2–4 unrelated muscular dystrophies (OPMD, MH, FSHD) were analyzed on western blot with specific antibodies for Tropomyosin
(A, at 35 kDa), BOC (B, at 110 and 45 kDa) and PIAS3 (D, at 60 kDa). The arrows denote the detected protein bands. C) Schematic model of PIAS3 E3
SUMO ligase activity, regulated by CAPN3. PIAS3 is involved in the covalent conjugation of Small Ubiquitin Like Modifier (SUMO) proteins to target
proteins. PIAS3 has a CAPN3 cleavage motif at the C-terminus. E) FLAG tagged PIAS1, 2, 3, and 4 were transiently expressed with active or inactive
CAPN3, and cleavage was analyzed on western blot with a FLAG specific antibody. Upon co-expression with active CAPN3 PIAS3, PIAS1 and PIAS2 are
A Calpain 3 Cleavage Motif
PLoS ONE | www.plosone.org 6 August 2010 | Volume 5 | Issue 8 | e11940muscle cells of these patients (Figure S5). Three disease controls
also failed to show SUMO2 staining in muscle. Taken together
this provides strong indication that CAPN3 regulates PIAS3
SUMO ligase activity in skeletal muscle.
Discussion
We have provided evidence that CAPN3 recognizes a primary
sequence motif in its substrates. We observed that peptides from
confirmed CAPN3 substrates contain the information for CAPN3
mediated cleavage and can transform a non-substrate into a
substrate. These peptides conform to a general motif of 4 key
residues that is found in many proteins, including all previously
reported substrates. Thus we provide a first explanation for why
CAPN3 cleaves these proteins. The second, more stringent motif
performs well in our biochemical assay. This is partly due to an
introduced bias based on resemblance to well performing peptides.
However, bioinformatics analysis of the putative substrates derived
from this motif highlights plausible substrate classes suchas apoptosis
and vesicle trafficking, substantiating the importance of CAPN3 as a
broad, yet specific regulator of cytoskeletal architecture. With the
motif new substrates can be efficiently predicted, as shown by the
increase in TPM and BOC levels in Calpainopathy patients and the
regulation of PIAS proteins by CAPN3.
We observed that molecular modeling experiments predict that
the peptide motif could be recognized by CAPN3. The mutation
analysis we performed for our motif might have a different
outcome when conducted within the folds of a different protein.
Nevertheless, cleavage of mouse Cyclin A (CCNA1, MIM*604036,
protein ID Q61456) by CAPN3 has been described. [27] The
authors show that when a small peptide (residue 120–130) is
deleted from this protein, cleavage is lost. Although this protein
was not included in our original screen it harbors a putative
cleavage site conforming to the first, general motif at residues 112–
121. This is fully consistent with the motif being targeted by
CAPN3 in its native protein environment.
For this study we did not consider actual determined cleavage
sites. Most of these are autolytic with cleavage taking place
intramolecularly within CAPN3, and their presentation could be
different from intermolecular cleavage. When comparing the
autolytic sites to the motif we found that all identified autolytic sites
strongly resemble the first motif ([LIMV]X(2–4)[LIMV][DEQ]).
We did find another peptide within CAPN3 that was functional in
our biochemical system and may represent a new autolytic
cleavage site. Intriguingly, 4 pathogenic amino acid substitutions
have been described that affect this peptide (www.dmd.nl/capn3).
Two mutations directly involve designated key residues, whereas
the other two target amino acids flanking key residues. Two of
these mutations show abnormal CAPN3 signal on western blot
[28,29], suggesting that these mutations may interfere with normal
CAPN3 autoregulation; a mechanism that was also recently
suggested by Garnham et al. [30]
The first step in the autolytic activation of CAPN3 is cleavage of
the internal IS1 sequence. It is interesting that the CAPN3 IS1
sequence contains a peptide that conforms to our first, general
motif. Diaz et al use the proteolytic core to show that IS1 is flanked
by two flexible autolytic sites. [31] Moreover, they model the IS1
sequence as an a-helix (secondary structure). Introducing a proline
mutation to disrupt this putative helix drastically increases the
autolytic properties of IS1. This is consistent with a preference of
the active core for flexible tertiary folds. We tested the IS1 peptide
in our system and could strongly increase its cleavage potential by
introducing a glycine at position 7 to increase flexibility (Table 1).
With our stringent motif we have predicted 325 CAPN3
substrates, whereas the first motif predicted several thousands of
substrates. This raises the question as to how specific CAPN3
cleavage is. The first motif is a common feature of many proteins
and suggests that the chance of CAPN3 encountering a substrate is
extremely high. CAPN3 activity would then be limited by its
means of activation and inactivation only. A protease that
recognizes thousands of substrates is potentially incredibly
destructive and needs a tight regulation of its own activity. This
would explain why CAPN3 protein is rapidly lost upon activation,
as was recently also suggested by Garnham et al [30]. The first
motif resembles the IS1 sequence, which acts as an inhibitory
peptide. [31] Loss of this peptide leaves the active site cavity open
for IS1 resembling structures; flexible non-structural protein loops
[9] with similarities to the inhibitory IS1 sequence that would fit
into the cavity. Among the peptides that fit are multiple sequences
of CAPN3 itself. Opening of the cavity not only results in
activation, but is rapidly followed by progressive autolysis and loss
of the protease. [8,32] Thus, both inhibition and inactivation are
self-regulated and CAPN3 activity is local by default, which
corroborates the previous model by Beckmann and Spencer [5].
This mechanism seems to plausibly reconcile the apparent
contradiction of a highly reactive protease, which yet recognizes
potentially thousands of protein substrates (Figure S6).
It is unclear whether the basic, more relaxed motif is sufficient
under all circumstances and many predicted targets will never
encounter the muscle-specific CAPN3. Moreover, the sarcomere-
bound form of CAPN3 is heavily restricted in its substrate
encounters due to a low diffusion rate. [5] CAPN3 2/2 mice
display misaligned sarcomeres[33] and cannot undergo cycles of
degeneration and regeneration indicating CAPN3 as an essential
muscleremodelingprotein.[34] Musclehasahighdemand forfocal
remodeling (exercise, repair, growth, etc) and would benefit greatly
from a localized unidirectional molecular remodeling switch. So a
highly reactive broad-spectrum protease that is specific, and which
is able to switch on and off irreversibly by itself, in a short time span,
is a plausible remodeling agent in such a tissue.
Previous mutation analyses indicated that most pathogenic
substitutions in CAPN3 either influence its activity directly or
indirectly by modifying its autolytic properties. [30] The broad
motif makes it unlikely that different CAPN3 mutations cause an
LGMD phenotype due to the deregulation of only one or two
substrates. Still it will be interesting to see whether mutations in
cleavage sites have been described for the uncovered substrates, and
with which phenotypic consequences. Of special interest is PIAS3,
which is a target for both CAPN3 and TRIM32 (MIM*602290).
[35] TRIM32 mutations cause LGMD2H (OMIM#254110), a
phenotype similar to LGMD2A. [36] Therefore PIAS regulation
may connect two genetically distinct types of LGMD.
It will be interesting to see whether our approach would also
work for other Calpain family members and compare their
predicted cleavage motifs, and substrate specificities. In addition,
methods are available [37] which may be used to improve the
cleaved at the C-terminus as predicted. PIAS4 is not cleaved. The arrows denote uncleaved and cleaved FLAG-PIAS. Nt means not transfected, + and –
refer to active and inactive CAPN3 respectively. F) PIAS3 was transiently expressed in an in vivo sumoylation assay with HIS6-SUMO1 or HIS6-SUMO2
and active or inactive CAPN3. Cells were lysed directly in sample buffer and sumoylation levels were estimated on western blot with a HIS antibody
(upper panel). Correct expression and CAPN3 mediated cleavage was confirmed with a FLAG antibody (lower panel).
doi:10.1371/journal.pone.0011940.g002
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long eluded the mechanism behind protein substrate recognition,
our studies show that molecular and data mining tools have




Patient biopsies were acquired through Dr. R Charlton,
Freeman Hospital, Newcastle-upon-Tyne, UK. All analyzed
patients had a confirmed molecular diagnosis, and met ethical
criteria for inclusion within the study including written informed
consent. All patients were recruited at Newcastle University,
according to the ethics committee there. Those biopsies that met
the criteria for inclusion in our study were send to us. Thus, no
patients were recruited specifically for our studies.
Patient mutation analysis
The unrelated muscular dystrophy cases were all genetically
confirmed and include patients with OPMD (1), MH (1) and FSHD
(2). LGMD2A patients had the following genetic mutations: P1)
X01:c.145C.T and X11:c.1468 C.T, P2) X02:c.327_328delCC
and X11:c.1477C.T, P3) X02: c.327_328dupCC and X11:
c.1435A.G, P4) X05:c.759_761delGAA and X11:c.1468C.T,
P5) X04:c.550delA and X11:c.1435A.G. P6) X05:c.633G.C and
X10:c.1319G.A. P7) X22:c.2314_2317delGACA. P3, P5 and P7
display a complete absence of CAPN3 protein. P1, P2 and P6 have
reduced CAPN3 protein levels. In P4 CAPN3 levels are normal.
Antibodies
RaGFP (1;5,000 Abcam), GaR-IRD680 and GaM-IRD800
(both 1;5,000 Westburg), MaCAPN3 NCL-12A2 (1;100 Novocas-
tra), MaTPM TM311 (1;2,000 Sigma), MaBOC (1;1,000 R&D),
RaPIAS3 (1;1,000 Santa Cruz), MaVSV P5D4 (1;5,000),
RaFLAG (1;2,000 Sigma), MaHIS6 (1;2,000 Cell signaling),
RaSUMO2/3 (1;5,000 gift from dr. A.C. Vertegaal, Leiden,
The Netherlands), MaDMD NCL-DYS2 (1;10 Novocastra),
GaM488 and GaR594 (1;750 and 1;2,000 Molecular Probes).
Cell culture
HEK293T[38]and MCF7[38]cellswereculturedinDulbecco’s
modified Eagle’s medium supplemented with Glucose, Pen/Strep
10% FCS and Glutamax (all Gibco-BRL) and grown at 37uCa n d
5% CO2.
DNA cloning and transfection
The b-Galactosidase-GFP (BG) and GFP- b-Galactosidase (GB)
vectors were a gift from Dr. JM Daniel, West Hamilton, Canada.
Target sequences were cloned by ligating pre-synthesized comple-
mentary primers (Invitrogen). Primer sequences available on request.
All constructs were sequence verified (LGTC, Leiden, The Nether-
lands). CAPN3 in pCDNA4 was a gift from Dr. K Bushby,
Newcastle, UK. The C129S mutant was constructed by site directed
mutagenesis and confirmed with direct sequencing (LGTC).
Expression vectors for HIS6-SUMO and FLAG-PIAS were a gift
from G. Roukens, LUMC, The Netherlands. DNA was transfected
with JET-PEI (Poly-Plus) according to manufacturers protocol. 48 h
post-transfection cells were washed and lysed in sample buffer.
Protein purification and mass spectrometry
Transiently transfected cells were lysed in ice cold lysis buffer
(50 mM Tris, pH7.4, 0.15M NaCl, 0.2% Triton X-100, 26
protease inhibitor cocktail (Roche)) and spun down 30 min, 4uC.
TALON resin (Clontech) was washed, pre-equilibrated and added
for 2 h 4uC, and subsequently spun down at 700 g, 4uC. The resin
was washed 3x and loaded on a column. A 300 bed volume wash
was followed by elution in 200 mM imidazole. Purified AHNAK
fragments were separated on SDS-PAGE gels and Coomassie Blue
stained bands in-gel digested and analyzed with LC-MS.
Fingerprints were screened with the MASCOT search engine.
SDS-PAGE, immunoblotting and immunohistochemistry were
performed as described before. [17] Coomassie Blue staining of
the gel after transfer was carried out to confirm equal loading.
Sequence analysis
Sequence analysis was done with web-based tools (www.expasy.
org). Protein sequences of described CAPN3 substrates were
retrieved from Uniprot (release 14.6) (http://www.expasy.org/
sprot/) and aligned in TEIRESIAS (http://cbcsrv.watson.ibm.
com/Tspd.html). [18] The following parameters resulted in motif
identification: Amino acids grouped according to chemical
properties, the minimum number of typical residues (L) was set
at 4, the maximum extent between two residues (W) was set at 10,
and the minimum number of proteins in which a pattern should
occur (K) was set at 10. The motif was [LIMV]X(4)[LIMV]X(2)
[LIMV][DE]. (Or [LIMV]X(3,4)[LIMV]X(2)[LIMV][DE] with
spacing variation.)
For the second motif the amino acids at each position for several
cleaved peptides was ‘‘added’’. As the first motif was thereby
discarded we started with the predicted functional peptides.
Adding of AHNAK2, CAPN3 and CAST gave: [LM][DPE]
[LSK][RFK][SK.][IMV][KPL][EKY][V][DE] with five protein
hits. Including AHNAK-C2.2 gave: [VLM][DPGE][LSIK]X(1,2)
[LIMV][KPL][EKY]V[DE]. Including the other AHNAK pep-
tides for consistency and the functional mutants that were not
conform the first motif gave: [VLM][DPGE][LAIGESK]X(1,2)
[LIMVA][KESQPL][GEKY][LVA][DE]. Careful examination of
all tested peptides revealed that glycine is present at site 4 only in
dysfunctional peptides. This brings the final stringent motif to
[VLM][PGED][SAGEKL]{G}X(0,1)[VAIML][ESPQLK][GKEY]
[VLA][ED] with 325 protein hits in human. On average the peptides
used to construct the motif contributed 18% to the motif, indicating
that the 325 predicted substrates were not identified based on a high
level of sequence identity to the test set (jackknife cross-validation [39]).
In statistical prediction, the following three test methods are often used
to examine a predictor for its effectiveness in practical application:
independent dataset test, subsampling (K-fold cross-validation) test,
and jackknife test [40]. However, as elucidated by [39] and
demonstrated by Eq.50 in [41], among the three cross-validation
methods, the jackknife test is deemed the most objective that can
always yield a unique result for a given benchmark dataset, and hence
has been increasingly used and widely recognized by investigators to
examine the accuracy of various predictors (see, e.g. [42–44]).
Accordingly, in this study the jackknife test was also adopted to
analyze the prediction quality.
The motifs were screened against the Swissprot database
(vs14.6, 16 Dec 2008) using ScanProsite (http://www.expasy.
org/tools/scanprosite/). [45–47] Default settings (no splice
variants, no overlap, not greedy) were applied, with a taxonomy
restriction for Homo sapiens.
MedLine analyses
The list of 325 predicted target proteins was analyzed with Anni
v2.0, a text mining tool that serves as an automated interface to
the biomedical literature (http://biosemantics.org/anni/). 193
proteins had a concept profile, i.e. a statistically weighted
A Calpain 3 Cleavage Motif
PLoS ONE | www.plosone.org 8 August 2010 | Volume 5 | Issue 8 | e11940summarization of the context in which the protein appears in
MedLine abstracts. For the other proteins there was not sufficient
information available in MedLine to construct a concept profile.
Which concepts (coming from the Unified Medical Language
System vocabulary (includes amongst others: disease, tissue,
cellular location, GO terms) were most strongly associated with
the proteins in the list was analyzed.
GO term analysis
A Gene Ontology analysis was done on the set of 325 predicted
proteins to find those GO terms that are most informative for the
set. The information content of a GO term is defined as the
negative log of the probability to find a subset of the proteins
annotated to that GO term.
IC GOterm ðÞ ~{log pGOterm ðÞ , where pGOterm is calculated using
the hyper geometric distribution. Every GO category is evaluated
individually. Biological process has 218, cellular component 239,
and molecular function 238 proteins annotated in the root node
respectively. The probability that a subset is annotated in the root
node always results in a probability of 1, and therefore has an
information content of 0. GO terms that are lower in the GO
hierarchy will have a higher information content in general.
Pathways were visualized with Matlab software.
SUMO2 pull-down
Transiently transfected HEK-293T cells were lysed by scraping
in 1 ml ice cold PBS with 2x protease inhibitor. An aliquot was
used to measure protein content and verify expression on western
blot. To the remaining lysate 3 ml denaturing buffer (6M
Guanidium 0.1M Na2HPO4/NaH2PO4, 0.01M Tris/HCl,
pH 8.0 plus 20 mM imidazole and 10 mM b-mercaptoethanol)
was added. Preequilibrated NTA beads were incubated 4 h 4uC
tumbling, spun down and washed. Subsequent washes with 8M
urea (plus 0.1 M Na2HPO4/NaH2PO4, 0.01 M Tris/HCl,
pH 8.0, 10 mM b-mercaptoethanol plus 0.2% Triton X-100) and
6M urea were followed by elution in 6M urea containing 200 mM
imidazole.
Structure analysis and docking
Secondary structure prediction was performed with two
different webtools: PSIPRED [48,49] and PHYRE [50].
The 3D structure of CAPN3 was obtained using homology
modeling of Swiss-Model Server (vs 8.05). [51] The structure of
CAPN2 (3DF0.pdb)[52] which shares 50% identity with CAPN3
was used as a model. (Calpain 4 and CAST structures were
discarded.) The FLNC structure (2D7P.pdb) was downloaded
from NCBI. Docking calculations were carried out with the
program Bigger [53,54], which requires as input the 3D structure
for each of the two interacting proteins CAPN3 (Target) and
FLNC (Probe). The structure of the complex is calculated through
a soft docking approach. The algorithm generates populations of
docked geometries with a maximal surface matching. The 500
model structures generated are ranked based on a computational
function. The simulation was carried out without experimental
restraints.
Supporting Information
Figure S1 Summary of peptide analysis corresponding to
Table 1. A) Multiple putative cleavage sequences from described
substrates were cloned into the BG fusion protein and co-
expressed with active (+) or inactive (2) CAPN3. Cells were
analyzed on western blot with RaGFP. Results for Ezrin (EZR),
Vinexin (SORBS3), and Talin (TLN1, 2 sites) are shown. Above
the blot the motif is shown. B) The predicted key residues of the
motif found in AHNAK-N were individually changed to alanine,
cloned into the BG fusion protein and tested by co-expression with
active or inactive CAPN3. Above the blot the AHNAK-N peptide
sequence in the BG fusion protein is shown. C) As in B) but now
for the peptide motif identified in FLNC. D) Several target
proteins that derive from the second, stringent motif screen were
tested in the BG fusion protein assay. Results for BOC, AP1B1,
AP2B1 and CTCF are shown. The fusion protein with AHNAK-
N peptide and its non-cleaved L9P mutant were used as controls.
The stringent motif sequence is depicted above the blot. E) The
assay yields comparable results in a GFP-BGal fusion protein. The
mutations shown in panel B were cloned in the "reversed" fusion
protein and tested by co-expression with active and inactive
CAPN3. In all panels arrows denote the uncleaved and cleaved
fusion protein.
Found at: doi:10.1371/journal.pone.0011940.s001 (1.44 MB TIF)
Figure S2 FLNC is predicted to dock into the active site of
CAPN3. A) We aligned the sequence of CAPN3 to that of Calpain
2 and modeled it onto the Calpain 2 structure, as done previously
for CAPN3. [13] We imported this structure together with FLNC
to a docking program (Bigger)[12] and allowed the software to
dock FLNC (containing the putative cleavage motif) onto the
CAPN3 structure without experimental restraints. The top 500
experimentally ranked docking solutions are shown. The structural
model of CAPN3 is depicted in blue, with the active site in pink
space fill. The dots represent the geometric center of FLNC in 500
docking solutions, ranked from red (high) to green (low)
probability. No solution brings FLNC close to the active site of
CAPN3. B) Same as in A) but the IS1 sequence of CAPN3, which
blocks the active site, was removed to mimic proteolytic activation.
Now, the docking solutions cluster towards the active site. C+D)
Ribbon image of a representative solution from the top 10. The 10
highest ranked solutions present the motif within reach of the
reactive cysteine. The modeled distances between the reactive
cysteine and activating histidine of CAPN3 and the motif are
(CAPN3-FLNC): C129-Y58=2.20A ˚, C129-E56=7.98A ˚, C129-
E61=8.90A ˚, H333-E56=3.34 A ˚. For Calpain 2 a distance of 5A ˚
is sufficient for cleavage. [52] Exchanging target (CAPN3) and
probe (FLNC) resulted in the exact same top ranked solutions.
Found at: doi:10.1371/journal.pone.0011940.s002 (9.43 MB TIF)
Figure S3 Data mining tools show conceptual overlap between
CAPN3 and the list of putative substrates. A) The software
program Anni was used to calculate concept profiles for all
substrates. The concepts were scored and ranked according to
occurrence. The concept "cytoskeletal proteins" is found most
often. The proteins that associate with this concept are listed in the
right column with in bold the proteins used in formation of the
motif. B) All proteins were first clustered according to conceptual
overlap, before annotating with concepts. Results were plotted in a
heat map, showing distinct protein clusters (corresponding table in
supplementary table S2). C) GO term analysis of the list of putative
substrates (full table in supplementary table S3). GO term
representation within the list was compared to the GO ontology
database. The top 20 enriched hits for cellular component were
analyzed with Matlab.
Found at: doi:10.1371/journal.pone.0011940.s003 (2.36 MB TIF)
Figure S4 Regulation of PIAS3 sumoylase activity by CAPN3.
A) In a SUMO2 pull down experiment the amount of SUMO2
conjugated proteins is decreased upon PIAS3 cleavage. HEK-
293T cells were transfected with HIS6 tagged SUMO2, FLAG-
PIAS3 and CAPN3 or CAPN3C129S, and cells were lysed 48 h
post transfection in 6M Guanidium. SUMO2 conjugates were
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Eluted proteins were analyzed for SUMO2 content on western
blot with a SUMO2 specific antibody. + Means transfected, nt
means non-transfected, - means transfected with inactive
CAPN3C129S. B) A SUMO2 pull down experiment shows that
PIAS3 autosumoylation is severely impaired upon CAPN3
mediated proteolytic cleavage. Cells were transfected as in A)
and HIS6 tagged SUMO2 conjugates were pulled down with
NTA beads. Pull down fractions were analyzed on western blot for
FLAG-PIAS3 content with a FLAG specific antibody. Blots depict
pulldown samples probed for FLAG-PIAS3 (upper panel) and pull
down input lysates probed for FLAG-PIAS3 and CAPN3 (middle
and bottom, respectively). Arrows denote sumoylated PIAS3, full-
length and cleaved PIAS3, and inactive and active CAPN3.
Found at: doi:10.1371/journal.pone.0011940.s004 (4.05 MB TIF)
Figure S5 SUMO2 is increased in myonuclei of LGMD2A
patients. Single cryosections of skeletal muscle of LGMD2a
patients P2 and P7, three healthy controls, and three disease
controls (MH, OPMD, FSHD) were stained for Dystrophin
(DMD, green, muscle membrane marker) and SUMO2 (red).
Nuclei are stained with DAPI in blue. Distinct nuclear dots are
seen in non-muscle nuclei (Arrowheads), and in LGMD2A
myonuclei (Large arrows).
Found at: doi:10.1371/journal.pone.0011940.s005 (4.59 MB TIF)
Figure S6 A model of CAPN3 function. Upon activation the
chance that CAPN3 will encounter a substrate is enormous. The
chance that the substrate is not CAPN3 is similarly high. However,
as proteolysis proceeds and the number of non-processed
substrates drops, the chance of CAPN3 encountering another
CAPN3 increases. This will automatically control the number of
active CAPN3 proteases inversely to the amount of processed
substrates. Thus CAPN3 activity is local by default.
Found at: doi:10.1371/journal.pone.0011940.s006 (0.77 MB TIF)
Table S1 325 predicted CAPN3 substrates. The specific motif
sequence was screened against UniProt with the webtool
ScanProsite, and yielded 325 unique proteins in human that
contain the motif. For each of the 325 proteins the following
information is listed: UniProt accession number, Protein ID, and
Gene ID. For 18 of the proteins the crystal structure had been
experimentally resolved. For these proteins a surface model of this
structure in included below (hyperlink), with in red the cleavage
motif.
Found at: doi:10.1371/journal.pone.0011940.s007 (1.72 MB
DOC)
Table S2 Conceptual clusters occurring in the list of putative
CAPN3 substrates. The 325 putative substrates were loaded into
the software program Anni and associated with concepts. The
concepts associated with the 325 putative substrates were grouped
into clusters and statistically weighed. The most significantly
occurring clusters were annotated with concepts. The first column
list the statistically weighed clusters, with in the second column the
associated concepts. The third column shows the genes belonging
to each cluster; with in bold those that tested positive in the fusion
protein assay.
Found at: doi:10.1371/journal.pone.0011940.s008 (0.29 MB
DOC)
Table S3 GO term annotation analysis for the putative CAPN3
substrates. Gene Ontology pathway analysis was performed on the
set of 325 putative substrates, to identity those pathways that are
most informative for the set. The first column shows the entropy,
where high entropy means a high content of information. The
second column lists the calculated numbers (Substrates belonging
to GO term | Absolute number of proteins belonging to GO term
pathway | Total proteins associated with GO term | Total
substrates in GO term pathway). In addition, the corresponding
GO term ID, GO Pathway, and GO term are given in the last
three columns. The top 20 hits for the Pathway Cellular
Component are plotted in Figure S2c. The Table was cut at an
entropy of 2.2669.
Found at: doi:10.1371/journal.pone.0011940.s009 (0.13 MB
DOC)
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